Literature DB >> 8634992

Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers.

S J Skates1, F J Xu, Y H Yu, K Sjövall, N Einhorn, Y Chang, R C Bast, R C Knapp.   

Abstract

Stored samples from women in the Stockholm screening study were reassayed for CA125II (Centocor, Malvern, PA) and OVX1. The postmenopausal women older than age 50 without ovarian cancer were randomly split into a training set to develop a screening test based on longitudinal marker levels and a second set to validate the test. The CA125II data from each woman is summarized by the slope and intercept from a linear regression of log(CA125II) on time since first sample. The slope versus the intercept for the training set and the ovarian cancer cases formed a bivariate scatter plot. A curve was drawn on the scatter plot that separated most of the women with ovarian cancer from all other women; it delineated a screening test. The specificity of this test was examined on the validation set with a specificity of 99.8%. Bayes' theorem was used to calculate the risk of ovarian cancer (ROC) based on the intercept, slope, and assay variability. It is important to account for assay variability because it can produce large slopes over short periods of time. The maximum risk, which identified 83% (5 of 6) of the ovarian cancers detected within a year of last assay, was applied as a test to the training set and confirmed a high specificity of 99.7%. With this specificity and sensitivity, the ROC algorithm using the CA125II assay has an estimated positive predictive value of 16%, substantially greater than the positive predictive value based on a single assay. Further study is planned to confirm the sensitivity of this approach.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8634992     DOI: 10.1002/1097-0142(19951115)76:10+<2004::aid-cncr2820761317>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  51 in total

1.  Screening for ovarian cancer. We now need a definitive randomised trial.

Authors:  N Urban
Journal:  BMJ       Date:  1999-11-20

2.  Measuring the intra-individual variability of the plasma proteome in the chicken model of spontaneous ovarian adenocarcinoma.

Authors:  Adam M Hawkridge; Rebecca B Wysocky; James N Petitte; Kenneth E Anderson; Paul E Mozdziak; Oscar J Fletcher; Jonathan M Horowitz; David C Muddiman
Journal:  Anal Bioanal Chem       Date:  2010-07-17       Impact factor: 4.142

3.  Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.

Authors:  Steven J Skates; Mark H Greene; Saundra S Buys; Phuong L Mai; Powel Brown; Marion Piedmonte; Gustavo Rodriguez; John O Schorge; Mark Sherman; Mary B Daly; Thomas Rutherford; Wendy R Brewster; David M O'Malley; Edward Partridge; John Boggess; Charles W Drescher; Claudine Isaacs; Andrew Berchuck; Susan Domchek; Susan A Davidson; Robert Edwards; Steven A Elg; Katie Wakeley; Kelly-Anne Phillips; Deborah Armstrong; Ira Horowitz; Carol J Fabian; Joan Walker; Patrick M Sluss; William Welch; Lori Minasian; Nora K Horick; Carol H Kasten; Susan Nayfield; David Alberts; Dianne M Finkelstein; Karen H Lu
Journal:  Clin Cancer Res       Date:  2017-01-31       Impact factor: 12.531

4.  Early detection of ovarian cancer.

Authors:  Partha M Das; Robert C Bast
Journal:  Biomark Med       Date:  2008-06       Impact factor: 2.851

Review 5.  Molecular signatures of ovarian cancer: from detection to prognosis.

Authors:  Christine S Walsh; Beth Y Karlan
Journal:  Mol Diagn Ther       Date:  2010-02-01       Impact factor: 4.074

Review 6.  The role of biomarkers in the management of epithelial ovarian cancer.

Authors:  Wei-Lei Yang; Zhen Lu; Robert C Bast
Journal:  Expert Rev Mol Diagn       Date:  2017-05-15       Impact factor: 5.225

7.  Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

Authors:  M W McIntosh; C Drescher; B Karlan; N Scholler; N Urban; K E Hellstrom; I Hellstrom
Journal:  Gynecol Oncol       Date:  2004-10       Impact factor: 5.482

8.  Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule.

Authors:  Charles W Drescher; Chirag Shah; Jason Thorpe; Kathy O'Briant; Garnet L Anderson; Christine D Berg; Nicole Urban; Martin W McIntosh
Journal:  J Clin Oncol       Date:  2012-12-17       Impact factor: 44.544

9.  A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study.

Authors:  Mark H Greene; Marion Piedmonte; Dave Alberts; Mitchell Gail; Martee Hensley; Zoe Miner; Phuong L Mai; Jennifer Loud; Gustavo Rodriguez; Jack Basil; John Boggess; Peter E Schwartz; Joseph L Kelley; Katie E Wakeley; Lori Minasian; Stephen Skates
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-03       Impact factor: 4.254

10.  Ovarian cancer pathogenesis: a model in evolution.

Authors:  Alison M Karst; Ronny Drapkin
Journal:  J Oncol       Date:  2009-09-06       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.